利用iTRAQ化學標定方法進行乳癌細胞系MCF-7多重抗藥性之差異蛋白質體學分析

Differential proteomic analysis of multidrug resistance in breast cancer cell line MCF-7 by iTRAQ technology

謝磊(Hsieh Lei)

指導教授 ： 陳頌方

國立臺灣師範大學/理學院/化學系/碩士(2020年)

https://doi.org/10.6345/NTNU202001590

摘要

無資料

關鍵字

差異蛋白質 ； 乳癌

並列摘要

無資料

並列關鍵字

iTRAQ ； differential protein ； breast cancer

參考文獻

1. Hulka, B. S.; Moorman, P. G., Reprint of Breast cancer: hormones and other risk factors. Maturitas 2008, 61 (1-2), 203-213.

2. Carter, P. J., Introduction to current and future protein therapeutics: a protein engineering perspective. Experimental cell research 2011, 317 (9), 1261-1269.

3. Burdall, S. E.; Hanby, A. M.; Lansdown, M. R.; Speirs, V., Breast cancer cell lines: friend or foe? Breast cancer research 2003, 5 (2), 1-7.

4. Horwitz, K.; Costlow, M.; McGuire, W., MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 1975, 26 (6), 785-795.

5. Shirazi, F. H.; Zarghi, A.; Ashtarinezhad, A.; Kobarfard, F.; Nakhjavani, M.; Anjidani, N.; Zendehdel, R.; Arfaiee, S.; Shoeibi, S.; Mohebi, S., Remarks in successful cellular investigations for fighting breast cancer using novel synthetic compounds. INTECH Open Access Publisher Croatia: 2011.